Generative AI in Drug Discovery Market Based on Technology(Deep learning, Machine learning, Reinforcement learning, Molecular docking, Quantum computing), Based on End-User(pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations (CROs), Other End-Users), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2024-2033
-
36823
-
April 2024
-
300
-
-
This report was compiled by Vishwa Gaul Vishwa is an experienced market research and consulting professional with over 8 years of expertise in the ICT industry, contributing to over 700 reports across telecommunications, software, hardware, and digital solutions. Correspondence Team Lead- ICT Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Quick Navigation
Report Overview
The Generative AI in Drug Discovery Market was valued at USD 138.5 Million in 2023. It is expected to reach USD 1,435.0 Million by 2033, with a CAGR of 27.1% during the forecast period from 2024 to 2033.
The surge in demand for new advanced technologies and the development of new drug discoveries as well as clinical trials are some of the main key factors for the generative artificial intelligence in drug discovery market. GenAI helps to focus on developing innovative data instances that are similar to the present data. It works on the fundamentals of unmonitored learning, where GenAI model learns and understands the patterns from a dataset without unambiguous labels. This permits GenAI to produce innovative and original samples like images, content, or text of drug discovery and molecular structure.
The emergence of various chronic diseases has raised the requirements for drug discovery. For example, according to CDC report that was published in December 2022, highlights that 6 out of 10 individuals have chronic diseases in the US and 4 out of 10 adults in the US have two or more. This has led to death and disability causes and the leading or well-known drivers of the nation have USD 4.1 trillion in annual health care expenses. Moreover, in 2022, there were numerous cases of cancer in India somewhere around 14,61,427. Similarly, in India, every 1 out of 9 individuals have cancer in their lifetime. Lung and breast cancers are some of the top cancers that are seen in males and females.
Additionally, according to an article published by Nature Medicines in 2023, Insilico Medicines declared its phase 1 safety and pharmacokinetics clinical trial of INS018_055 which is powered by AI for idiopathic pulmonary fibrosis, an advanced disease which is caused due to damaging of the lungs. This will help in recognizing new targets and small molecule inhibitors which were approved by FDA in February 2023. There are several advantages of implementing GenAI in drug discovery such as it helps in fastening the drug discovery process, decreases expenses, and targets rare diseases with customized medicines.
This technology also helps in the research and development of clinical trials tracking, manages record keeping, and helps in clinical trials feedback summarizations. The demand for GenAI will increase due to its requirement in various clinical trials and medical hubs that will help in market expansion in the coming years.
Key Takeaways
- Market Growth: The Generative AI in Drug Discovery Market was valued at USD 138.5 Million in 2023. It is expected to reach USD 1,435.0 Million by 2033, with a CAGR of 27.1% during the forecast period from 2024 to 2033.
- Based on Technology: Deep learning dominates Generative AI in Drug Discovery technology, capturing 36% market share.
- Based on End-User: Pharmaceutical and biotech firms lead as primary end-users, claiming 42% dominance.
- Regional Dominance: North America holds 49% of the global Generative AI in drug discovery market.
- Growth Opportunity: Generative AI significantly advances personalized medicine and rare disease treatments by customizing drugs to individual genetics and efficiently exploring novel therapies, thus transforming the drug discovery market in 2023.
Driving factors
Rising Prevalence of Chronic Diseases Fuels Demand for Efficient Drug Discovery
The escalating burden of chronic diseases worldwide necessitates a rapid and effective response from the pharmaceutical industry. Generative AI in drug discovery offers a promising solution by accelerating the identification of potential therapeutic compounds. With conditions such as cancer, diabetes, and cardiovascular diseases becoming more prevalent, there's a growing urgency to streamline drug discovery processes. Generative AI presents an opportunity to expedite the identification of novel compounds, reducing the time and cost involved in traditional methods.
Demand for Cost-effective Drug Discovery Drives Adoption of Generative AI
As healthcare costs continue to rise, pharmaceutical companies seek cost-effective alternatives to traditional drug discovery approaches. Generative AI offers a compelling solution by optimizing resource utilization and reducing the need for extensive compound screening. Leveraging machine learning algorithms, enables the generation of virtual compound libraries, minimizing the expenses associated with physical synthesis and testing. This increased efficiency aligns with the industry's goal of maximizing value while minimizing expenditure, thereby driving the adoption of generative AI in drug discovery. The Generative AI in Life Sciences Market is revolutionizing drug discovery, enhancing speed and predictive accuracy.
Overcoming Limitations of Traditional Drug Discovery Processes
The conventional drug discovery process is characterized by its time-consuming and expensive nature, often involving the screening of vast numbers of compounds. Generative AI addresses these limitations by significantly accelerating the compound identification process.
By leveraging computational models and predictive analytics, it can efficiently generate and prioritize candidate molecules for further evaluation. This transformative approach not only expedites drug discovery timelines but also reduces associated costs, making it an attractive proposition for pharmaceutical companies seeking innovation and efficiency.
Restraining Factors
High Cost of Implementation
The High Cost of Implementation poses a significant initial barrier to entry for companies seeking to adopt Generative AI in Drug Discovery. However, despite the upfront expenses, the long-term benefits outweigh these costs. Companies that invest in Generative AI technologies witness improved efficiency and reduced time-to-market for drug development.
By automating various stages of the drug discovery process, including molecule generation and screening, Generative AI streamlines operations, ultimately leading to cost savings in the long run. As more companies recognize the potential for cost reduction and efficiency gains, they are increasingly willing to allocate resources to implement Generative AI solutions.
Data Privacy Concerns
Data privacy concerns have been a prevalent issue in the healthcare and pharmaceutical industries, where sensitive patient data and proprietary research information are at stake. However, advancements in privacy-preserving technologies, such as federated learning and differential privacy, address these concerns by allowing collaboration and data sharing without compromising confidentiality.
Additionally, regulatory bodies like the FDA and EMA have stringent guidelines in place to ensure compliance with data privacy regulations, fostering trust among stakeholders. As a result, companies are more inclined to adopt Generative AI solutions for drug discovery, knowing that patient privacy and data security are adequately safeguarded.
Based on Technology Analysis
With Deep Learning dominating 36% of the market, its advanced capabilities propel innovation in drug discovery.
In 2023, Deep learning held a dominant market position in the Based on Technology segment of the Generative AI in Drug Discovery Market, capturing more than a 36% share. Deep learning algorithms have revolutionized the field of drug discovery by efficiently analyzing vast amounts of data to predict molecular interactions and identify potential drug candidates. Its ability to learn from large datasets and extract meaningful patterns has made it indispensable in the quest for novel therapeutics.
Machine learning followed closely behind, accounting for approximately 28% of the market share. Machine learning techniques, including supervised, unsupervised, and semi-supervised learning, have been instrumental in predicting molecular properties, optimizing drug design processes, and streamlining drug development pipelines.
Reinforcement learning emerged as another significant player in the market, constituting around 18% of the segment share. With its ability to make sequential decisions and optimize drug discovery processes through trial and error, reinforcement learning has shown promise in accelerating the identification of lead compounds and optimizing drug dosages.
Molecular docking techniques accounted for approximately 12% of the market share. Molecular docking plays a crucial role in predicting the binding affinity and orientation of small molecules to target proteins, aiding in the rational design of new drugs, and understanding ligand-protein interactions at the atomic level.
Quantum computing, although still in its nascent stages, accounted for the remaining 6% of the segment share. Quantum computing holds the potential to revolutionize drug discovery by solving complex computational problems at speeds exponentially faster than classical computers, opening new avenues for simulating molecular structures and accelerating drug design processes.
Based on End-User Analysis
Pharmaceutical and biotechnology companies, dominating 42%, drive demand for Generative AI solutions in research.
In 2023, pharmaceutical and biotechnology companies held a dominant market position in the Based on End-User segment of the Generative AI in Drug Discovery Market, capturing more than a 42% share. These companies have been at the forefront of adopting generative AI technologies to streamline their drug discovery processes, from target identification to lead optimization. The significant investment in research and development, coupled with the pressing need to bring novel therapeutics to market, has propelled pharmaceutical and biotechnology companies to lead in the adoption of AI-driven drug discovery solutions.
Academic and research institutions followed closely behind, accounting for approximately 30% of the segment share. These institutions serve as vital hubs of innovation, collaborating with industry partners and leveraging generative AI technologies to advance scientific knowledge and develop new treatments for various diseases. The availability of funding and access to cutting-edge research facilities have enabled academic and research institutions to actively engage in AI-driven drug discovery initiatives.
Contract research organizations (CROs) constituted around 20% of the market share in the segment. CROs play a pivotal role in providing specialized services to pharmaceutical companies, ranging from early-stage drug discovery to clinical trials. The integration of generative AI tools into CRO operations has enhanced their ability to deliver efficient and cost-effective solutions to their clients, driving the adoption of AI technologies across the drug development landscape.
Other End-Users, including government agencies, non-profit organizations, and healthcare providers, accounted for the remaining 8% of the segment share. While their contribution to the market is relatively smaller, these entities play essential roles in supporting and regulating drug discovery efforts, fostering collaboration, and ensuring equitable access to innovative therapies.
Key Market Segments
Based on Technology
- Deep learning
- Machine learning
- Reinforcement learning
- Molecular docking
- Quantum computing
Based on End-User
- pharmaceutical and biotechnology companies
- academic and research institutions
- contract research organizations (CROs)
- Other End-Users
Growth Opportunity
Personalized Medicine
The integration of Generative AI into the drug discovery process heralds significant advancements in personalized medicine. This technology is poised to revolutionize the pharmaceutical landscape by enabling the identification and development of customized drug therapies that cater to individual genetic profiles. The capacity of Generative AI to analyze vast datasets quickly and accurately can significantly enhance the efficacy of treatments while minimizing adverse side effects.
As a result, the adoption of Generative AI is expected to accelerate the production of targeted therapies, thereby fostering market growth and improving patient outcomes. The potential for Generative AI in this sector is vast, with its ability to transform the approach towards personalized healthcare solutions.
Rare Disease Treatments
Generative AI offers promising opportunities in the realm of rare disease treatment. Rare diseases, often overlooked due to the high cost and complexity of developing specific treatments, can benefit from the AI's ability to rapidly generate and evaluate novel drug compounds. By leveraging its computational power, Generative AI can uncover therapeutic possibilities that human researchers may not consider, efficiently exploring chemical and biological interactions at scale.
This capability addresses a critical gap in the healthcare sector by facilitating the development of effective treatments for rare conditions, thus meeting a significant unmet medical need. The growth in this segment is anticipated to contribute substantially to the overall expansion of the global Generative AI drug discovery market.
Latest Trends
Drug Molecule Creation
In 2023, one of the most prominent trends in the global Generative AI in drug discovery market is its application in de novo drug design. Generative AI is increasingly used to create new drug molecules, a process that enhances the speed and efficiency of drug discovery. By simulating millions of potential interactions and predicting how different chemical structures may behave, AI tools enable researchers to identify novel compounds with high therapeutic potential faster than traditional methods.
This application of Generative AI not only accelerates the research and development phase but also increases the likelihood of breakthroughs in medicine, offering a considerable advantage in the competitive pharmaceutical industry.
Target Identification and Drug Repurposing
Another significant trend is the use of Generative AI in target identification and drug repurposing. This technology assists in pinpointing new uses for existing drugs, thereby extending their lifecycle and enhancing their value in the market. Through sophisticated analysis and pattern recognition, Generative AI can identify previously unrecognized biological targets or new therapeutic potentials for established drugs.
This not only speeds up the process of drug development but also significantly cuts costs and reduces risks associated with the development of brand-new drugs. The ability to repurpose drugs with the aid of AI is transforming pharmaceutical strategies and operations, marking a critical shift towards more efficient and flexible drug development practices in 2023.
Regional Analysis
In 2023, North America holds a 49% share of the global Generative AI in drug discovery market.
North America, dominating the market with a 49% share, leads in the adoption of Generative AI technologies due to its advanced healthcare infrastructure, substantial investments in AI and biotechnology, and the presence of major pharmaceutical and biotech companies. This region benefits from a robust regulatory framework supporting AI integration into healthcare and drug development, which significantly drives innovation and market growth.
Europe follows closely, characterized by its strong academic and research base, particularly in countries like Germany, the UK, and France. The European market is bolstered by increasing government funding and collaborations between AI tech firms and pharmaceutical giants, focusing on accelerating drug discovery processes through AI applications. The region's emphasis on innovation and sustainable healthcare solutions further supports the market's expansion.
Asia Pacific is identified as a rapidly growing segment in the Generative AI in drug discovery market. This growth is fueled by rising healthcare expenditure, growing biotech industries, and increasing governmental support in countries such as China, Japan, and South Korea. The region's market is expanding due to its improvements in healthcare infrastructure and the escalating demand for personalized medicine.
Middle East & Africa and Latin America are emerging regions showing promising growth. These regions are gradually adopting AI technologies, driven by the need to enhance healthcare services and develop solutions for regional disease burdens. Although these regions currently hold smaller market shares, their growth is supported by gradual investments in health tech and increasing awareness of the potential benefits of AI in healthcare.
Key Regions and Countries
North America
- The US
- Canada
- Rest of North America
Europe
- Germany
- France
- The UK
- Spain
- Netherlands
- Russia
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- Singapore
- Thailand
- South Korea
- Vietnam
- India
- New Zealand
- Rest of Asia Pacific
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of Middle East & Africa
Key Players Analysis
In 2023, the landscape of the global Generative AI in Drug Discovery market has been markedly shaped by several key players, each contributing unique approaches and technologies to accelerate drug discovery processes through artificial intelligence.
Insilico Medicine has continued to distinguish itself with its AI-driven platforms that enhance the speed and efficiency of drug development. The company's use of deep learning techniques to predict the pharmacological properties of molecules significantly shortens the preclinical development phase.
Atomwise Inc. leverages its AI algorithms for structure-based drug design, significantly reducing the time and costs associated with identifying candidate molecules. Their AtomNet platform uses convolutional neural networks, setting a high standard in predicting molecule behavior.
BenevolentAI stands out for its integrated computational and experimental technologies to decipher complex biomedical data. The company's AI systems provide valuable insights into disease mechanisms, which in turn accelerates the identification of novel therapeutic targets.
XtalPi Inc. combines quantum mechanics and machine learning to predict molecular properties with remarkable accuracy, thus providing reliable data for drug design and development phases.
Numerate Inc. employs AI to automate the drug design process, focusing on addressing the pharmacokinetics and safety profiles of new drugs, enhancing the predictability of successful drug candidates.
Cyclica Inc. offers a platform that utilizes AI to consider both the polypharmacological profiles of molecules and their potential off-target effects, aiming to increase the success rates in the drug development pipeline.
BioSymetrics, while lesser known, is instrumental in preprocessing complex biomedical data, thus enabling more efficient data utilization in AI models.
Market Key Players
- Insilico Medicine
- Atomwise Inc.
- BenevolentAI
- XtalPi Inc
- Numerate Inc
- Cyclica Inc
- BioSymetrics
- Other Key Players
Recent Development
- In March 2024, AWS and NVIDIA announced extending collaboration to offer NVIDIA Grace Blackwell GPU-based Amazon EC2 instances and DGX Cloud, accelerating generative AI innovation in healthcare and life sciences, and advancing drug discovery.
- In February 2024, Almirall S.A. partnered with Microsoft to enhance drug discovery in dermatology using AI. They aim to accelerate innovation, optimize operations, and empower digital transformation in dermatological treatments.
- In January 2024, GHDDI and Microsoft Research utilize AI to accelerate drug discovery for global infectious diseases, achieving remarkable progress in designing small-molecule inhibitors for Mycobacterium tuberculosis and coronaviruses in just five months.
Report Scope
Report Features Description Market Value (2023) USD 138.5 Million Forecast Revenue (2033) USD 1,435.0 Million CAGR (2024-2032) 27.1% Base Year for Estimation 2023 Historic Period 2016-2023 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered Based on Technology(Deep learning, Machine learning, Reinforcement learning, Molecular docking, Quantum computing), Based on End-User(pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations (CROs), Other End-Users) Regional Analysis North America - The US, Canada, Rest of North America, Europe - Germany, France, The UK, Spain, Italy, Russia, Netherlands, Rest of Europe, Asia-Pacific - China, Japan, South Korea, India, New Zealand, Singapore, Thailand, Vietnam, Rest of Asia Pacific, Latin America - Brazil, Mexico, Rest of Latin America, Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa Competitive Landscape Insilico Medicine, Atomwise Inc., BenevolentAI, XtalPi Inc., Numerate Inc., Cyclica Inc., BioSymetrics, Other Key Players Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) -
- 1. Executive Summary
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 1.4. Key Analysis
- 1.5. Key Findings by Major Segments
- 1.6. Top strategies by Major Players
- 2. Global Generative AI in Drug Discovery Market Overview
- 2.1. Generative AI in Drug Discovery Market Dynamics
- 2.1.1. Drivers
- 2.1.2. Opportunities
- 2.1.3. Restraints
- 2.1.4. Challenges
- 2.2. Macro-economic Factors
- 2.3. Regulatory Framework
- 2.4. Market Investment Feasibility Index
- 2.5. PEST Analysis
- 2.6. PORTER’S Five Force Analysis
- 2.7. Drivers & Restraints Impact Analysis
- 2.8. Industry Chain Analysis
- 2.9. Cost Structure Analysis
- 2.10. Marketing Strategy
- 2.11. Russia-Ukraine War Impact Analysis
- 2.12. Opportunity Map Analysis
- 2.13. Market Competition Scenario Analysis
- 2.14. Product Life Cycle Analysis
- 2.15. Opportunity Orbits
- 2.16. Manufacturer Intensity Map
- 2.17. Major Companies sales by Value & Volume
- 2.1. Generative AI in Drug Discovery Market Dynamics
- 3. Global Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, 2016-2032
- 3.1. Global Generative AI in Drug Discovery Market Analysis, 2016-2021
- 3.2. Global Generative AI in Drug Discovery Market Opportunity and Forecast, 2023-2032
- 3.3. Global Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Based on Technology, 2016-2032
- 3.3.1. Global Generative AI in Drug Discovery Market Analysis by Based on Technology: Introduction
- 3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Based on Technology, 2016-2032
- 3.3.3. Deep learning
- 3.3.4. Machine learning
- 3.3.5. Reinforcement learning
- 3.3.6. Molecular docking
- 3.3.7. Quantum computing
- 3.4. Global Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Based on End-User, 2016-2032
- 3.4.1. Global Generative AI in Drug Discovery Market Analysis by Based on End-User: Introduction
- 3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Based on End-User, 2016-2032
- 3.4.3. pharmaceutical and biotechnology companies
- 3.4.4. academic and research institutions
- 3.4.5. contract research organizations (CROs)
- 3.4.6. Other End-Users
- 4. North America Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, 2016-2032
- 4.1. North America Generative AI in Drug Discovery Market Analysis, 2016-2021
- 4.2. North America Generative AI in Drug Discovery Market Opportunity and Forecast, 2023-2032
- 4.3. North America Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Based on Technology, 2016-2032
- 4.3.1. North America Generative AI in Drug Discovery Market Analysis by Based on Technology: Introduction
- 4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Based on Technology, 2016-2032
- 4.3.3. Deep learning
- 4.3.4. Machine learning
- 4.3.5. Reinforcement learning
- 4.3.6. Molecular docking
- 4.3.7. Quantum computing
- 4.4. North America Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Based on End-User, 2016-2032
- 4.4.1. North America Generative AI in Drug Discovery Market Analysis by Based on End-User: Introduction
- 4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Based on End-User, 2016-2032
- 4.4.3. pharmaceutical and biotechnology companies
- 4.4.4. academic and research institutions
- 4.4.5. contract research organizations (CROs)
- 4.4.6. Other End-Users
- 4.5. North America Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 4.5.1. North America Generative AI in Drug Discovery Market Analysis by Country : Introduction
- 4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 4.5.2.1. The US
- 4.5.2.2. Canada
- 4.5.2.3. Mexico
- 5. Western Europe Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, 2016-2032
- 5.1. Western Europe Generative AI in Drug Discovery Market Analysis, 2016-2021
- 5.2. Western Europe Generative AI in Drug Discovery Market Opportunity and Forecast, 2023-2032
- 5.3. Western Europe Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Based on Technology, 2016-2032
- 5.3.1. Western Europe Generative AI in Drug Discovery Market Analysis by Based on Technology: Introduction
- 5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Based on Technology, 2016-2032
- 5.3.3. Deep learning
- 5.3.4. Machine learning
- 5.3.5. Reinforcement learning
- 5.3.6. Molecular docking
- 5.3.7. Quantum computing
- 5.4. Western Europe Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Based on End-User, 2016-2032
- 5.4.1. Western Europe Generative AI in Drug Discovery Market Analysis by Based on End-User: Introduction
- 5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Based on End-User, 2016-2032
- 5.4.3. pharmaceutical and biotechnology companies
- 5.4.4. academic and research institutions
- 5.4.5. contract research organizations (CROs)
- 5.4.6. Other End-Users
- 5.5. Western Europe Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 5.5.1. Western Europe Generative AI in Drug Discovery Market Analysis by Country : Introduction
- 5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 5.5.2.1. Germany
- 5.5.2.2. France
- 5.5.2.3. The UK
- 5.5.2.4. Spain
- 5.5.2.5. Italy
- 5.5.2.6. Portugal
- 5.5.2.7. Ireland
- 5.5.2.8. Austria
- 5.5.2.9. Switzerland
- 5.5.2.10. Benelux
- 5.5.2.11. Nordic
- 5.5.2.12. Rest of Western Europe
- 6. Eastern Europe Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, 2016-2032
- 6.1. Eastern Europe Generative AI in Drug Discovery Market Analysis, 2016-2021
- 6.2. Eastern Europe Generative AI in Drug Discovery Market Opportunity and Forecast, 2023-2032
- 6.3. Eastern Europe Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Based on Technology, 2016-2032
- 6.3.1. Eastern Europe Generative AI in Drug Discovery Market Analysis by Based on Technology: Introduction
- 6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Based on Technology, 2016-2032
- 6.3.3. Deep learning
- 6.3.4. Machine learning
- 6.3.5. Reinforcement learning
- 6.3.6. Molecular docking
- 6.3.7. Quantum computing
- 6.4. Eastern Europe Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Based on End-User, 2016-2032
- 6.4.1. Eastern Europe Generative AI in Drug Discovery Market Analysis by Based on End-User: Introduction
- 6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Based on End-User, 2016-2032
- 6.4.3. pharmaceutical and biotechnology companies
- 6.4.4. academic and research institutions
- 6.4.5. contract research organizations (CROs)
- 6.4.6. Other End-Users
- 6.5. Eastern Europe Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 6.5.1. Eastern Europe Generative AI in Drug Discovery Market Analysis by Country : Introduction
- 6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 6.5.2.1. Russia
- 6.5.2.2. Poland
- 6.5.2.3. The Czech Republic
- 6.5.2.4. Greece
- 6.5.2.5. Rest of Eastern Europe
- 7. APAC Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, 2016-2032
- 7.1. APAC Generative AI in Drug Discovery Market Analysis, 2016-2021
- 7.2. APAC Generative AI in Drug Discovery Market Opportunity and Forecast, 2023-2032
- 7.3. APAC Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Based on Technology, 2016-2032
- 7.3.1. APAC Generative AI in Drug Discovery Market Analysis by Based on Technology: Introduction
- 7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Based on Technology, 2016-2032
- 7.3.3. Deep learning
- 7.3.4. Machine learning
- 7.3.5. Reinforcement learning
- 7.3.6. Molecular docking
- 7.3.7. Quantum computing
- 7.4. APAC Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Based on End-User, 2016-2032
- 7.4.1. APAC Generative AI in Drug Discovery Market Analysis by Based on End-User: Introduction
- 7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Based on End-User, 2016-2032
- 7.4.3. pharmaceutical and biotechnology companies
- 7.4.4. academic and research institutions
- 7.4.5. contract research organizations (CROs)
- 7.4.6. Other End-Users
- 7.5. APAC Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 7.5.1. APAC Generative AI in Drug Discovery Market Analysis by Country : Introduction
- 7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 7.5.2.1. China
- 7.5.2.2. Japan
- 7.5.2.3. South Korea
- 7.5.2.4. India
- 7.5.2.5. Australia & New Zeland
- 7.5.2.6. Indonesia
- 7.5.2.7. Malaysia
- 7.5.2.8. Philippines
- 7.5.2.9. Singapore
- 7.5.2.10. Thailand
- 7.5.2.11. Vietnam
- 7.5.2.12. Rest of APAC
- 8. Latin America Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, 2016-2032
- 8.1. Latin America Generative AI in Drug Discovery Market Analysis, 2016-2021
- 8.2. Latin America Generative AI in Drug Discovery Market Opportunity and Forecast, 2023-2032
- 8.3. Latin America Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Based on Technology, 2016-2032
- 8.3.1. Latin America Generative AI in Drug Discovery Market Analysis by Based on Technology: Introduction
- 8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Based on Technology, 2016-2032
- 8.3.3. Deep learning
- 8.3.4. Machine learning
- 8.3.5. Reinforcement learning
- 8.3.6. Molecular docking
- 8.3.7. Quantum computing
- 8.4. Latin America Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Based on End-User, 2016-2032
- 8.4.1. Latin America Generative AI in Drug Discovery Market Analysis by Based on End-User: Introduction
- 8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Based on End-User, 2016-2032
- 8.4.3. pharmaceutical and biotechnology companies
- 8.4.4. academic and research institutions
- 8.4.5. contract research organizations (CROs)
- 8.4.6. Other End-Users
- 8.5. Latin America Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 8.5.1. Latin America Generative AI in Drug Discovery Market Analysis by Country : Introduction
- 8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 8.5.2.1. Brazil
- 8.5.2.2. Colombia
- 8.5.2.3. Chile
- 8.5.2.4. Argentina
- 8.5.2.5. Costa Rica
- 8.5.2.6. Rest of Latin America
- 9. Middle East & Africa Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, 2016-2032
- 9.1. Middle East & Africa Generative AI in Drug Discovery Market Analysis, 2016-2021
- 9.2. Middle East & Africa Generative AI in Drug Discovery Market Opportunity and Forecast, 2023-2032
- 9.3. Middle East & Africa Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Based on Technology, 2016-2032
- 9.3.1. Middle East & Africa Generative AI in Drug Discovery Market Analysis by Based on Technology: Introduction
- 9.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Based on Technology, 2016-2032
- 9.3.3. Deep learning
- 9.3.4. Machine learning
- 9.3.5. Reinforcement learning
- 9.3.6. Molecular docking
- 9.3.7. Quantum computing
- 9.4. Middle East & Africa Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Based on End-User, 2016-2032
- 9.4.1. Middle East & Africa Generative AI in Drug Discovery Market Analysis by Based on End-User: Introduction
- 9.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Based on End-User, 2016-2032
- 9.4.3. pharmaceutical and biotechnology companies
- 9.4.4. academic and research institutions
- 9.4.5. contract research organizations (CROs)
- 9.4.6. Other End-Users
- 9.5. Middle East & Africa Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 9.5.1. Middle East & Africa Generative AI in Drug Discovery Market Analysis by Country : Introduction
- 9.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 9.5.2.1. Algeria
- 9.5.2.2. Egypt
- 9.5.2.3. Israel
- 9.5.2.4. Kuwait
- 9.5.2.5. Nigeria
- 9.5.2.6. Saudi Arabia
- 9.5.2.7. South Africa
- 9.5.2.8. Turkey
- 9.5.2.9. The UAE
- 9.5.2.10. Rest of MEA
- 10. Global Generative AI in Drug Discovery Market Analysis, Opportunity and Forecast, By Region , 2016-2032
- 10.1. Global Generative AI in Drug Discovery Market Analysis by Region : Introduction
- 10.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
- 10.2.1. North America
- 10.2.2. Western Europe
- 10.2.3. Eastern Europe
- 10.2.4. APAC
- 10.2.5. Latin America
- 10.2.6. Middle East & Africa
- 11. Global Generative AI in Drug Discovery Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 11.1. Market Share Analysis
- 11.2. Company Profiles
- 11.3. Insilico Medicine
- 11.3.1. Company Overview
- 11.3.2. Financial Highlights
- 11.3.3. Product Portfolio
- 11.3.4. SWOT Analysis
- 11.3.5. Key Strategies and Developments
- 11.4. Atomwise Inc.
- 11.4.1. Company Overview
- 11.4.2. Financial Highlights
- 11.4.3. Product Portfolio
- 11.4.4. SWOT Analysis
- 11.4.5. Key Strategies and Developments
- 11.5. BenevolentAI
- 11.5.1. Company Overview
- 11.5.2. Financial Highlights
- 11.5.3. Product Portfolio
- 11.5.4. SWOT Analysis
- 11.5.5. Key Strategies and Developments
- 11.6. XtalPi Inc
- 11.6.1. Company Overview
- 11.6.2. Financial Highlights
- 11.6.3. Product Portfolio
- 11.6.4. SWOT Analysis
- 11.6.5. Key Strategies and Developments
- 11.7. Numerate Inc
- 11.7.1. Company Overview
- 11.7.2. Financial Highlights
- 11.7.3. Product Portfolio
- 11.7.4. SWOT Analysis
- 11.7.5. Key Strategies and Developments
- 11.8. Cyclica Inc
- 11.8.1. Company Overview
- 11.8.2. Financial Highlights
- 11.8.3. Product Portfolio
- 11.8.4. SWOT Analysis
- 11.8.5. Key Strategies and Developments
- 11.9. BioSymetrics
- 11.9.1. Company Overview
- 11.9.2. Financial Highlights
- 11.9.3. Product Portfolio
- 11.9.4. SWOT Analysis
- 11.9.5. Key Strategies and Developments
- 11.10. Other Key Players
- 11.10.1. Company Overview
- 11.10.2. Financial Highlights
- 11.10.3. Product Portfolio
- 11.10.4. SWOT Analysis
- 11.10.5. Key Strategies and Developments
- 11.13.1. Company Overview
- 11.13.2. Financial Highlights
- 11.13.3. Product Portfolio
- 11.13.4. SWOT Analysis
- 11.13.5. Key Strategies and Developments
- 12. Assumptions and Acronyms
- 13. Research Methodology
- 14. Contact
"
- List of Figures
- "
- Figure 1: Global Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Based on Technology in 2022
- Figure 2: Global Generative AI in Drug Discovery Market Market Attractiveness Analysis by Based on Technology, 2016-2032
- Figure 3: Global Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Based on End-Userin 2022
- Figure 4: Global Generative AI in Drug Discovery Market Market Attractiveness Analysis by Based on End-User, 2016-2032
- Figure 5: Global Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Region in 2022
- Figure 6: Global Generative AI in Drug Discovery Market Market Attractiveness Analysis by Region, 2016-2032
- Figure 7: Global Generative AI in Drug Discovery Market Market Revenue (US$ Mn) (2016-2032)
- Figure 8: Global Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Figure 9: Global Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on Technology (2016-2032)
- Figure 10: Global Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on End-User (2016-2032)
- Figure 11: Global Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Figure 12: Global Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on Technology (2016-2032)
- Figure 13: Global Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on End-User (2016-2032)
- Figure 14: Global Generative AI in Drug Discovery Market Market Share Comparison by Region (2016-2032)
- Figure 15: Global Generative AI in Drug Discovery Market Market Share Comparison by Based on Technology (2016-2032)
- Figure 16: Global Generative AI in Drug Discovery Market Market Share Comparison by Based on End-User (2016-2032)
- Figure 17: North America Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Based on Technologyin 2022
- Figure 18: North America Generative AI in Drug Discovery Market Market Attractiveness Analysis by Based on Technology, 2016-2032
- Figure 19: North America Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Based on End-Userin 2022
- Figure 20: North America Generative AI in Drug Discovery Market Market Attractiveness Analysis by Based on End-User, 2016-2032
- Figure 21: North America Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 22: North America Generative AI in Drug Discovery Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 23: North America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) (2016-2032)
- Figure 24: North America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 25: North America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on Technology (2016-2032)
- Figure 26: North America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on End-User (2016-2032)
- Figure 27: North America Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 28: North America Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on Technology (2016-2032)
- Figure 29: North America Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on End-User (2016-2032)
- Figure 30: North America Generative AI in Drug Discovery Market Market Share Comparison by Country (2016-2032)
- Figure 31: North America Generative AI in Drug Discovery Market Market Share Comparison by Based on Technology (2016-2032)
- Figure 32: North America Generative AI in Drug Discovery Market Market Share Comparison by Based on End-User (2016-2032)
- Figure 33: Western Europe Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Based on Technologyin 2022
- Figure 34: Western Europe Generative AI in Drug Discovery Market Market Attractiveness Analysis by Based on Technology, 2016-2032
- Figure 35: Western Europe Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Based on End-Userin 2022
- Figure 36: Western Europe Generative AI in Drug Discovery Market Market Attractiveness Analysis by Based on End-User, 2016-2032
- Figure 37: Western Europe Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 38: Western Europe Generative AI in Drug Discovery Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 39: Western Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) (2016-2032)
- Figure 40: Western Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 41: Western Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on Technology (2016-2032)
- Figure 42: Western Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on End-User (2016-2032)
- Figure 43: Western Europe Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 44: Western Europe Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on Technology (2016-2032)
- Figure 45: Western Europe Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on End-User (2016-2032)
- Figure 46: Western Europe Generative AI in Drug Discovery Market Market Share Comparison by Country (2016-2032)
- Figure 47: Western Europe Generative AI in Drug Discovery Market Market Share Comparison by Based on Technology (2016-2032)
- Figure 48: Western Europe Generative AI in Drug Discovery Market Market Share Comparison by Based on End-User (2016-2032)
- Figure 49: Eastern Europe Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Based on Technologyin 2022
- Figure 50: Eastern Europe Generative AI in Drug Discovery Market Market Attractiveness Analysis by Based on Technology, 2016-2032
- Figure 51: Eastern Europe Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Based on End-Userin 2022
- Figure 52: Eastern Europe Generative AI in Drug Discovery Market Market Attractiveness Analysis by Based on End-User, 2016-2032
- Figure 53: Eastern Europe Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 54: Eastern Europe Generative AI in Drug Discovery Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 55: Eastern Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) (2016-2032)
- Figure 56: Eastern Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 57: Eastern Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on Technology (2016-2032)
- Figure 58: Eastern Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on End-User (2016-2032)
- Figure 59: Eastern Europe Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 60: Eastern Europe Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on Technology (2016-2032)
- Figure 61: Eastern Europe Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on End-User (2016-2032)
- Figure 62: Eastern Europe Generative AI in Drug Discovery Market Market Share Comparison by Country (2016-2032)
- Figure 63: Eastern Europe Generative AI in Drug Discovery Market Market Share Comparison by Based on Technology (2016-2032)
- Figure 64: Eastern Europe Generative AI in Drug Discovery Market Market Share Comparison by Based on End-User (2016-2032)
- Figure 65: APAC Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Based on Technologyin 2022
- Figure 66: APAC Generative AI in Drug Discovery Market Market Attractiveness Analysis by Based on Technology, 2016-2032
- Figure 67: APAC Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Based on End-Userin 2022
- Figure 68: APAC Generative AI in Drug Discovery Market Market Attractiveness Analysis by Based on End-User, 2016-2032
- Figure 69: APAC Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 70: APAC Generative AI in Drug Discovery Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 71: APAC Generative AI in Drug Discovery Market Market Revenue (US$ Mn) (2016-2032)
- Figure 72: APAC Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 73: APAC Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on Technology (2016-2032)
- Figure 74: APAC Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on End-User (2016-2032)
- Figure 75: APAC Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 76: APAC Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on Technology (2016-2032)
- Figure 77: APAC Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on End-User (2016-2032)
- Figure 78: APAC Generative AI in Drug Discovery Market Market Share Comparison by Country (2016-2032)
- Figure 79: APAC Generative AI in Drug Discovery Market Market Share Comparison by Based on Technology (2016-2032)
- Figure 80: APAC Generative AI in Drug Discovery Market Market Share Comparison by Based on End-User (2016-2032)
- Figure 81: Latin America Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Based on Technologyin 2022
- Figure 82: Latin America Generative AI in Drug Discovery Market Market Attractiveness Analysis by Based on Technology, 2016-2032
- Figure 83: Latin America Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Based on End-Userin 2022
- Figure 84: Latin America Generative AI in Drug Discovery Market Market Attractiveness Analysis by Based on End-User, 2016-2032
- Figure 85: Latin America Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 86: Latin America Generative AI in Drug Discovery Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 87: Latin America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) (2016-2032)
- Figure 88: Latin America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 89: Latin America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on Technology (2016-2032)
- Figure 90: Latin America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on End-User (2016-2032)
- Figure 91: Latin America Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 92: Latin America Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on Technology (2016-2032)
- Figure 93: Latin America Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on End-User (2016-2032)
- Figure 94: Latin America Generative AI in Drug Discovery Market Market Share Comparison by Country (2016-2032)
- Figure 95: Latin America Generative AI in Drug Discovery Market Market Share Comparison by Based on Technology (2016-2032)
- Figure 96: Latin America Generative AI in Drug Discovery Market Market Share Comparison by Based on End-User (2016-2032)
- Figure 97: Middle East & Africa Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Based on Technologyin 2022
- Figure 98: Middle East & Africa Generative AI in Drug Discovery Market Market Attractiveness Analysis by Based on Technology, 2016-2032
- Figure 99: Middle East & Africa Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Based on End-Userin 2022
- Figure 100: Middle East & Africa Generative AI in Drug Discovery Market Market Attractiveness Analysis by Based on End-User, 2016-2032
- Figure 101: Middle East & Africa Generative AI in Drug Discovery Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 102: Middle East & Africa Generative AI in Drug Discovery Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 103: Middle East & Africa Generative AI in Drug Discovery Market Market Revenue (US$ Mn) (2016-2032)
- Figure 104: Middle East & Africa Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 105: Middle East & Africa Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on Technology (2016-2032)
- Figure 106: Middle East & Africa Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on End-User (2016-2032)
- Figure 107: Middle East & Africa Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 108: Middle East & Africa Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on Technology (2016-2032)
- Figure 109: Middle East & Africa Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on End-User (2016-2032)
- Figure 110: Middle East & Africa Generative AI in Drug Discovery Market Market Share Comparison by Country (2016-2032)
- Figure 111: Middle East & Africa Generative AI in Drug Discovery Market Market Share Comparison by Based on Technology (2016-2032)
- Figure 112: Middle East & Africa Generative AI in Drug Discovery Market Market Share Comparison by Based on End-User (2016-2032)
"
- List of Tables
- "
- Table 1: Global Generative AI in Drug Discovery Market Market Comparison by Based on Technology (2016-2032)
- Table 2: Global Generative AI in Drug Discovery Market Market Comparison by Based on End-User (2016-2032)
- Table 3: Global Generative AI in Drug Discovery Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 4: Global Generative AI in Drug Discovery Market Market Revenue (US$ Mn) (2016-2032)
- Table 5: Global Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 6: Global Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on Technology (2016-2032)
- Table 7: Global Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on End-User (2016-2032)
- Table 8: Global Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Table 9: Global Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on Technology (2016-2032)
- Table 10: Global Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on End-User (2016-2032)
- Table 11: Global Generative AI in Drug Discovery Market Market Share Comparison by Region (2016-2032)
- Table 12: Global Generative AI in Drug Discovery Market Market Share Comparison by Based on Technology (2016-2032)
- Table 13: Global Generative AI in Drug Discovery Market Market Share Comparison by Based on End-User (2016-2032)
- Table 14: North America Generative AI in Drug Discovery Market Market Comparison by Based on End-User (2016-2032)
- Table 15: North America Generative AI in Drug Discovery Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 16: North America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) (2016-2032)
- Table 17: North America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 18: North America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on Technology (2016-2032)
- Table 19: North America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on End-User (2016-2032)
- Table 20: North America Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 21: North America Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on Technology (2016-2032)
- Table 22: North America Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on End-User (2016-2032)
- Table 23: North America Generative AI in Drug Discovery Market Market Share Comparison by Country (2016-2032)
- Table 24: North America Generative AI in Drug Discovery Market Market Share Comparison by Based on Technology (2016-2032)
- Table 25: North America Generative AI in Drug Discovery Market Market Share Comparison by Based on End-User (2016-2032)
- Table 26: Western Europe Generative AI in Drug Discovery Market Market Comparison by Based on Technology (2016-2032)
- Table 27: Western Europe Generative AI in Drug Discovery Market Market Comparison by Based on End-User (2016-2032)
- Table 28: Western Europe Generative AI in Drug Discovery Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 29: Western Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) (2016-2032)
- Table 30: Western Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 31: Western Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on Technology (2016-2032)
- Table 32: Western Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on End-User (2016-2032)
- Table 33: Western Europe Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 34: Western Europe Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on Technology (2016-2032)
- Table 35: Western Europe Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on End-User (2016-2032)
- Table 36: Western Europe Generative AI in Drug Discovery Market Market Share Comparison by Country (2016-2032)
- Table 37: Western Europe Generative AI in Drug Discovery Market Market Share Comparison by Based on Technology (2016-2032)
- Table 38: Western Europe Generative AI in Drug Discovery Market Market Share Comparison by Based on End-User (2016-2032)
- Table 39: Eastern Europe Generative AI in Drug Discovery Market Market Comparison by Based on Technology (2016-2032)
- Table 40: Eastern Europe Generative AI in Drug Discovery Market Market Comparison by Based on End-User (2016-2032)
- Table 41: Eastern Europe Generative AI in Drug Discovery Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 42: Eastern Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) (2016-2032)
- Table 43: Eastern Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 44: Eastern Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on Technology (2016-2032)
- Table 45: Eastern Europe Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on End-User (2016-2032)
- Table 46: Eastern Europe Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 47: Eastern Europe Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on Technology (2016-2032)
- Table 48: Eastern Europe Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on End-User (2016-2032)
- Table 49: Eastern Europe Generative AI in Drug Discovery Market Market Share Comparison by Country (2016-2032)
- Table 50: Eastern Europe Generative AI in Drug Discovery Market Market Share Comparison by Based on Technology (2016-2032)
- Table 51: Eastern Europe Generative AI in Drug Discovery Market Market Share Comparison by Based on End-User (2016-2032)
- Table 52: APAC Generative AI in Drug Discovery Market Market Comparison by Based on Technology (2016-2032)
- Table 53: APAC Generative AI in Drug Discovery Market Market Comparison by Based on End-User (2016-2032)
- Table 54: APAC Generative AI in Drug Discovery Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 55: APAC Generative AI in Drug Discovery Market Market Revenue (US$ Mn) (2016-2032)
- Table 56: APAC Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 57: APAC Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on Technology (2016-2032)
- Table 58: APAC Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on End-User (2016-2032)
- Table 59: APAC Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 60: APAC Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on Technology (2016-2032)
- Table 61: APAC Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on End-User (2016-2032)
- Table 62: APAC Generative AI in Drug Discovery Market Market Share Comparison by Country (2016-2032)
- Table 63: APAC Generative AI in Drug Discovery Market Market Share Comparison by Based on Technology (2016-2032)
- Table 64: APAC Generative AI in Drug Discovery Market Market Share Comparison by Based on End-User (2016-2032)
- Table 65: Latin America Generative AI in Drug Discovery Market Market Comparison by Based on Technology (2016-2032)
- Table 66: Latin America Generative AI in Drug Discovery Market Market Comparison by Based on End-User (2016-2032)
- Table 67: Latin America Generative AI in Drug Discovery Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 68: Latin America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) (2016-2032)
- Table 69: Latin America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 70: Latin America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on Technology (2016-2032)
- Table 71: Latin America Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on End-User (2016-2032)
- Table 72: Latin America Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 73: Latin America Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on Technology (2016-2032)
- Table 74: Latin America Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on End-User (2016-2032)
- Table 75: Latin America Generative AI in Drug Discovery Market Market Share Comparison by Country (2016-2032)
- Table 76: Latin America Generative AI in Drug Discovery Market Market Share Comparison by Based on Technology (2016-2032)
- Table 77: Latin America Generative AI in Drug Discovery Market Market Share Comparison by Based on End-User (2016-2032)
- Table 78: Middle East & Africa Generative AI in Drug Discovery Market Market Comparison by Based on Technology (2016-2032)
- Table 79: Middle East & Africa Generative AI in Drug Discovery Market Market Comparison by Based on End-User (2016-2032)
- Table 80: Middle East & Africa Generative AI in Drug Discovery Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 81: Middle East & Africa Generative AI in Drug Discovery Market Market Revenue (US$ Mn) (2016-2032)
- Table 82: Middle East & Africa Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 83: Middle East & Africa Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on Technology (2016-2032)
- Table 84: Middle East & Africa Generative AI in Drug Discovery Market Market Revenue (US$ Mn) Comparison by Based on End-User (2016-2032)
- Table 85: Middle East & Africa Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 86: Middle East & Africa Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on Technology (2016-2032)
- Table 87: Middle East & Africa Generative AI in Drug Discovery Market Market Y-o-Y Growth Rate Comparison by Based on End-User (2016-2032)
- Table 88: Middle East & Africa Generative AI in Drug Discovery Market Market Share Comparison by Country (2016-2032)
- Table 89: Middle East & Africa Generative AI in Drug Discovery Market Market Share Comparison by Based on Technology (2016-2032)
- Table 90: Middle East & Africa Generative AI in Drug Discovery Market Market Share Comparison by Based on End-User (2016-2032)
- 1. Executive Summary
-
- Insilico Medicine
- Atomwise Inc.
- BenevolentAI
- XtalPi Inc
- Numerate Inc
- Cyclica Inc
- BioSymetrics
- Other Key Players
Our Clients
View Our Licence Options
